Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer

Authors: M Cummings, L Maraqa, MB Peter, AM Shaaban, AM Hanby, MA Hull, V Speirs

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Tamoxifen has been the principal endocrine therapy for estrogen receptor alpha (ERα)-positive breast cancer patients and still remains the therapy of choice in the premenopausal setting. However, resistance and recurrence remain a serious problem. Our previous work has indicated that 15-hydroxyprostaglandin dehydrogenase (15-PGDH) was significantly down-regulated in two, independently derived, tamoxifen-resistant (TAMr) MCF-7 derivatives compared with sensitive controls [1]. 15-PGDH is the key enzyme for the biological inactivation of prostaglandins, and has been shown to be a tumour suppressor in breast cancer. However, a role for 15-PGDH downregulation in endocrine resistance has not previously been identified. …
Literature
1.
Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V: Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol. 2007, 31: 557-565.PubMed
Metadata
Title
Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer
Authors
M Cummings
L Maraqa
MB Peter
AM Shaaban
AM Hanby
MA Hull
V Speirs
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1914

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

Proapoptotic protein Bid is regulated by phosphorylation during anoikis and the cell cycle

Poster presentation

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer

Poster presentation

Multicentre study of CASP8 polymorphisms in breast cancer

Poster presentation

TARGIT: an international trial of intraoperative versus external beam radiotherapy

Poster presentation

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours

Poster presentation

Discrepancies and challenge of ductal carcinoma in situfor health professionals
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits